CD19 and acute lymphoblastic leukemia: In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy (tisagenlecleucel) indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukemia (ALL) became the first gene therapy to be approved in the USA (1).